# Novartis AG (NVS) stock: price, valuation and fundamentals

URL: https://funkfolio.com/stock/NVS

> Novartis AG (NVS) trades at $159.16, is worth $300.59B, is priced at 30.4× earnings and scores 67/100. Valuation, financials and signals.

---

## Novartis AG (NVS)

Novartis AG (NVS) is a healthcare company (drug manufacturers - general) based in Switzerland. The share price is $159.16, down 0.65% on the day, which values the company at $300.59B. Price as of 17 Nov 2026, 21:00 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $159.16 −0.65% today
- **Market value:** $300.59B
- **P/E ratio:** 30.4× last 12 months
- **Forward P/E:** 16.0×
- **Dividend yield:** 2.91%
- **Funk Score:** 67/100
- **Against its own history:** Well above its usual price usual price $119.27
- **200-week average:** $117.59 35% above

Figures as of 17 Nov 2026, 21:00 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Novartis AG in more detail

NVS trades at 30.4× its last twelve months' earnings, 16.0× next year's expected earnings, 5.2× sales. Measured against its own history, the price is 33% above what its usual multiples would imply ($119.27) — well above its usual price. It sits 35% above its 200-week average of $117.59.

Its Funk Score is 67 out of 100 (financial strength 7.3, profitability 9.7, growth 7.7, value 2.0, each out of 10).

In its favour: Strong Piotroski score; Share count keeps falling.

13 of the superinvestors tracked here hold NVS, including Tweedy, Browne team (0.8% of the portfolio), Ken Fisher (0.7% of the portfolio), Primecap team (0.6% of the portfolio).

### Superinvestors holding NVS

13 of the investors tracked here report a position in their latest 13F filing.

- [Tweedy, Browne team Tweedy, Browne Company](https://funkfolio.com/gurus/tweedy-browne) 0.80% of portfolio · $9.8M · trimmed · Q3 2026
- [Ken Fisher Fisher Investments](https://funkfolio.com/gurus/ken-fisher) 0.69% of portfolio · $2.4B · added · Q3 2026
- [Primecap team Primecap Management](https://funkfolio.com/gurus/primecap) 0.58% of portfolio · $938.9M · trimmed · Q3 2026
- [Brandon Haley Holocene Advisors](https://funkfolio.com/gurus/brandon-haley) 0.37% of portfolio · $162.6M · new · Q2 2026
- [Larry Robbins Glenview Capital Management](https://funkfolio.com/gurus/larry-robbins) 0.27% of portfolio · $13.6M · new · Q2 2026
- [Thomas Kahn Kahn Brothers](https://funkfolio.com/gurus/thomas-kahn) 0.27% of portfolio · $1.6M · trimmed · Q3 2026
- [Andrew Spokes Farallon Capital Management](https://funkfolio.com/gurus/farallon) 0.19% of portfolio · $36.4M · trimmed · Q3 2026
- [Charles Brandes (founder) Brandes Investment Partners](https://funkfolio.com/gurus/charles-brandes) 0.18% of portfolio · $26.7M · trimmed · Q3 2026
- [Jeremy Grantham (co-founder) GMO (Grantham, Mayo, Van Otterloo)](https://funkfolio.com/gurus/jeremy-grantham) 0.09% of portfolio · $40.2M · added · Q3 2026
- [Dodge & Cox team Dodge & Cox](https://funkfolio.com/gurus/dodge-and-cox) 0.06% of portfolio · $104.8M · trimmed · Q3 2026
- [Lee Ainslie Maverick Capital](https://funkfolio.com/gurus/lee-ainslie) 0.04% of portfolio · $4.4M · added · Q2 2026
- [Murray Stahl Horizon Kinetics](https://funkfolio.com/gurus/murray-stahl) 0.02% of portfolio · $1.4M · trimmed · Q3 2026
- [Rajiv Jain GQG Partners](https://funkfolio.com/gurus/rajiv-jain) 0.01% of portfolio · $6.7M · trimmed · Q3 2026

### Health Care companies of similar size

- [Eli Lilly LLY](https://funkfolio.com/stock/LLY)
- [Johnson & Johnson JNJ](https://funkfolio.com/stock/JNJ)
- [AbbVie ABBV](https://funkfolio.com/stock/ABBV)
- [Merck & Co MRK](https://funkfolio.com/stock/MRK)
- [UnitedHealth Group UNH](https://funkfolio.com/stock/UNH)
- [AstraZeneca AZN](https://funkfolio.com/stock/AZN)
- [Thermo Fisher Scientific TMO](https://funkfolio.com/stock/TMO)
- [Amgen AMGN](https://funkfolio.com/stock/AMGN)
- [Gilead Sciences GILD](https://funkfolio.com/stock/GILD)
- [Abbott Laboratories ABT](https://funkfolio.com/stock/ABT)
- [Novo Nordisk NVO](https://funkfolio.com/stock/NVO)
- [Pfizer PFE](https://funkfolio.com/stock/PFE)

Side by side: [NVS vs AZN (Novartis AG vs AstraZeneca)](https://funkfolio.com/compare/azn-vs-nvs) [NVS vs UNH (Novartis AG vs UnitedHealth Group)](https://funkfolio.com/compare/nvs-vs-unh) [NVS vs MRK (Novartis AG vs Merck & Co)](https://funkfolio.com/compare/mrk-vs-nvs) [NVS vs TMO (Novartis AG vs Thermo Fisher Scientific)](https://funkfolio.com/compare/nvs-vs-tmo) [NVS vs ABBV (Novartis AG vs AbbVie)](https://funkfolio.com/compare/abbv-vs-nvs)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in Switzerland](https://funkfolio.com/companies/country/switzerland) [All stocks A–Z](https://funkfolio.com/stocks)

### Novartis AG (NVS): questions and answers

**What is NVS's P/E ratio?**

Novartis AG trades at 30.4× its last twelve months' earnings and 16.0× next year's expected earnings. At its fiscal year-ends over the past 4 years the P/E ranged from 14.2× to 28.6×, with a median of 17.9×.

**What is NVS's PEG ratio?**

Novartis AG's PEG ratio is 3.81 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

**What is Novartis AG's market cap?**

Novartis AG is valued at $300.59B at a share price of $159.16.

**Is NVS overvalued or undervalued?**

Against its own history, NVS is well above its usual price: the price is 33% above the $119.27 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

**Is NVS above its 200-week moving average?**

Yes. NVS is 35.3% above its 200-week average of $117.59. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is Novartis AG growing?**

Over the last three fiscal years Novartis AG's revenue grew 9.3% a year and its earnings per share 31.1% a year.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Novartis AG (NVS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/NVS

Underlying data: Yahoo Finance; company filings with the SEC.
